Phase 3 N=356 Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival — 28.5; 25.3 months — p=0.2853
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=17 Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
Brain Tumor · Brain Metastases
Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response
N/A N=40 Stereotactic Radiation Therapy in Treating Patients With Brain Metastases
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients Dying of Neurological Death, Defined as Dying With Progressive Neurological Dysfunction Regardless of Systemic Disease Status — 5 patients
Phase 2 N=3 Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer
Central Nervous System Metastases · Leptomeningeal Metastases · Recurrent Breast Cancer
Primary: Survival Free of Neurological Progression, Measured in Weeks — 6 weeks
Phase 3 N=472 Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
Lung Cancer, Non-Small Cell
Primary: Overall Survival — 4.0; 3.6 months — p=0.1862
Phase 2 N=51 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Brain Metastasis · Bladder Cancer · Breast Cancer
Primary: Local Control — 13; 23; 2; 1 participants
N/A N=22 Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc
Neoplasm Metastasis
Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants
N/A N=14 Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer
Breast Cancer · Leptomeningeal Metastasis
Primary: Total Number of Participants With Leptomeningeal Metastasis Detected (ER Status) — 3; 1 Participants
N/A N=41 A Proof-of-principle Study of HBO-SRS for Brain Metastases
Brain Metastases
Primary: The Average Time From HBO Chamber Exit to SRS beam-on — 8.3 minutes
Phase 2 N=26 Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
Lung Cancer · Metastatic Cancer
Primary: Number of Patients With Intracranial Response — 3 participants
Phase 2 N=55 Epothilone B in Treating Patients With CNS Metastases From Breast Cancer
Breast Cancer · Metastatic Cancer
Primary: Central Nervous System (CNS) Progression-free Survival(PFS) — 12; 2 participants
N/A N=52 MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
Brain Metastases
Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume
N/A N=11 Analyzing Preoperative Stereotactic Radiosurgery With Gamma Knife Icon for Brain Metastases
Brain Metastases
Primary: The Number of Subjects Undergoing Resection Following SRS. — 11 Participants
N/A N=15 Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis
Malignant Solid Neoplasm
Primary: Contrast to Noise Ratio — 3.2 Ratio — p=< 0.05
Phase 3 N=213 Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Breast Cancer · Cognitive/Functional Effects · Lung Cancer
Primary: Neurocognitive Progression as Measured by the Number of Participants With Cognitive Deterioration by 3 Months — 40; 44 Participants — p=<0.001
N/A N=24 Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis
Metastatic Malignant Neoplasm to Brain · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Maximum Tolerated Dose (MTD) of Hypofractionated Radiosurgery Defined as the Highest Dose Level Where a Grade 3 or Greater With an Attribution Score of ≥ 3 Develops in ≤…
Phase 2 N=58 GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases
Melanoma · Brain Metastases
Primary: 1-year Survival Rate — 31.8 Percentage of patients alive at 1 year
N/A N=24 Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain Metastases
Malignant Neoplasm Brain
Primary: Local Control Rate (LCR) at 6 Months — 0.817 proportion of patients
N/A N=15 Radiosurgery and Avastin for Recurrent Malignant Gliomas
Malignant Glioma
Primary: Central Nervous System (CNS) Toxicity — 1 participants
N/A N=13 Managing Distress in Malignant Brain Cancer
Cancer Metastatic to Brain · Brain Metastases, Adult
Primary: Assess the Need for Adaptations to the CALM Intervention as Measured by the Applicability of the 4 CALM Domains — 3.2; 4.0; 4.0; 3.5 score on a scale
N/A N=13 A Dose Escalation Trial of Five Fraction Stereotactic Radiation Therapy for Brain Metastases
Brain Metastases
Primary: Maximum Tolerated Dose of Five Fraction Stereotactic Radiotherapy — 35; 30 Gy
N/A N=128 A Study For Using Radiosurgery On Limited Metastases
Neoplasms, Metastatic
Primary: Percentage of Curatively Treated Patients With Progression-free Survival — 16 percentage of participants
Phase 2 N=49 Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases
Metastatic Cancer
Primary: Radiographic Response Assessed by Macdonald Criteria Every 2 Months — 3; 2; 4; 3 participants
Phase 2 N=265 Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer
Lung Cancer
Primary: Incidence of Chronic Neurotoxicity — 60; 85; 89 percentage of participants
Phase 2 N=40 High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement
B-cell Lymphomas
Primary: Event-free Survival — 16 Participants
Phase 2 N=78 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Brain and Central Nervous System Tumors · Intraocular Melanoma · Lung Cancer
Primary: Six-month Overall Survival — 67; 11 Participants
Phase 2 N=18 Ipilimumab and Nivolumab in Leptomeningeal Metastases
Leptomeningeal Carcinomatosis
Primary: Percentage of Participants With Overall Survival — 44 percentage of participants
N/A N=56 Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
Brain Cancer · Neoplasm Metastasis · Cancer of Brain and Nervous System
Primary: Stereotactic Radiosurgery (SRS) Maximum-tolerated Dose (MTD) — 0; 0; 0; 0 Dose-limited toxicity (DLT) events
Phase 3 N=194 Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery
Cognitive/Functional Effects · Metastatic Cancer · Neurotoxicity
Primary: Cognitive Deterioration Free Survival Post-radiation in Patients Who Received SRS Compared to Patients Who Received WBRT — 3.0; 3.7 Months — p=<0.0001
Phase 2 N=65 MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Melanoma · Non-Small Cell Lung Cancer · Brain Metastases
Primary: Overall Response in the Brain by mRECIST — 17; 31; 6; 11 participants